KYMR Stock Analysis
KY
Uncovered
Kymera Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. The company is headquartered in Watertown, Massachusetts and currently employs 167 full-time employees. The company went IPO on 2020-08-21. The firm is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Its targeted protein degradation (TPD) platform Pegasus allows it to discover selective small molecule protein degraders with activity against disease-causing proteins throughout the body. The Company’s Pegasus platform includes E3 Ligase Whole-Body Atlas, E3 Ligase Binders Toolbox, Ternary Complex Modeling and Quantitative System Pharmacology Model. The Company’s clinical-stage programs include IRAK4, IRAKIMiD, and STAT3, which each address targets within the interleukin-1 receptor/toll-like receptor (IL-1R/TLR), and janus kinase/signal transducers and activators of transcription (JAK/STAT). The Company’s programs focus on treating range of immune-inflammatory diseases, hematologic malignancies, and solid tumors.